IP Library › Granted Patent US 12,357,704
Granted Patent B2
US 12,357,704 · App. 17/605,214 · Granted Jul 15, 2025

Tailored hypoimmune nanovesicular delivery systems for cancer tumors

Inventor: Thomas Malcolm (Andover, NJ)
Assignee: Thomas Malcolm
A61K47/6901A61K9/5068C07K14/7051C07K2317/622C07K2319/33C12N2501/515C12N2506/45C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,704
App. No.
17/605,214
Granted
Jul 15, 2025
Kind
B2
Abstract

Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived biomimetic nanovesicles (hypo-bioNVs) including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers through an antibody fragment scFV region or by a viral epitope recognition receptor (VERR). A method of making hypo-bioNVs. A method of treating an individual with cancer, by administering the hypo-bioNVs to an individual, targeting cancer cells, and treating the cancer. A method of targeting cells in an individual, by administering the hypo-bioNVs to an individual, and targeting cells to be destroyed or treated.

Claims (29)

1. A hypoimmunogenic induced pluripotent stem cell (iPSC)-derived biomimetic nanovesicle (hypo-BioNV) comprising a surface coated with one or more chimeric antigen receptor (CAR) comprising an antibody single chain variable fragment (scFv) or a viral epitope recognition receptor (VERR),

wherein the hypo-BioNV is comprised of cell membrane of a gene-edited hypoimmunogenic iPSC,

wherein the gene-edited hypoimmunogenic iPSC, and hypo-bioNV derived therefrom, is HLA1 negative, HLA2 negative, PD1 negative, and CD47 negative,

wherein the hypo-BioNV recognizes one or more target biomarkers through the antibody fragment scFv region or VERR, and

wherein the hypo-BioNV encapsulates and is capable of delivering one or more of a small molecule, biologic, nucleic acid, and/or gene editing therapeutic to a cellular target that expresses the one or more target biomarkers.

2. The hypo-BioNV of claim 1 , wherein the hypo-BioNV surface further comprises Fas Ligand and/or neural cell adhesion molecule (NCAM).

3. The hypo-BioNV of claim 1 , wherein the hypo-BioNV encapsulates perforin, granzyme, or perforin and granzyme.

4. The hypo-BioNV of claim 1 , wherein the iPSC is derived from CD34+ cord blood.

5. The hypo-BioNV of claim 1 , wherein the nucleic acid comprises one or more gene, gene fragment, exon, intron, messenger RNA (mRNA), transfer RNA, ribosomal RNA, siRNA, micro-RNA, short hairpin RNA (shRNA), interfering RNA (RNAi), ribozyme, cDNA, recombinant polynucleotides, branched polynucleotides, plasmid, vector, isolated DNA, isolated RNA, nucleic acid probe, nucleic acid primer, and nucleic acid analog.

6. The hypo-BioNV of claim 1 , wherein the gene editing therapeutic comprises one or more gRNA or a plasmid encoding the one or more gRNA.

7. The hypo-BioNV of claim 1 , wherein the gene editing therapeutic comprises one or more of a transcription activator-like effector nuclease (TALEN), zinc finger nuclease (ZFN), RNase P RNA, C2c1, C2c2, C2c3, Cas9, Cpf1, TevCas9, Archaea Cas9, CasY.1, CasY.2, CasY.3, CasY.4, CasY.5, CasY.6, or CasX.

8. The hypo-BioNV of claim 1 , wherein the hypo-BioNV has a size of 300 nm to 1000 nm, or wherein the hypo-BioNV has a size of 1000 nm to 1200 nm.

9. The hypo-BioNV of claim 1 , wherein the VERR comprises vp1, vp2, or vp3 of SVV.

10. The hypo-BioNV of claim 1 , wherein the hypo-BioNV comprises a surface having HIV gp120/gp41 or ApoE.

11. A hypoimmunogenic induced pluripotent stem cell (iPSC)-derived biomimetic nanovesicle (hypo-BioNV) comprising a surface coated with one or more chimeric antigen receptor (CAR) comprising an antibody single chain variable fragment (scFv) or a viral epitope recognition receptor (VERR),

wherein the hypo-bioNV is comprised of cell membrane of a gene-edited hypoimmunogenic iPSC,

wherein the gene-edited hypoimmunogenic iPSC, and hypo-bioNV derived therefrom, is HLA1 negative, HLA2 negative, and PD1 negative, and lacks CD47,

wherein the hypo-BioNV has a size of 300 nm to 1000 nm or 1000 nm to 1200 nm,

wherein the hypo-BioNV recognizes one or more target biomarkers through the antibody fragment scFv or VERR, and

wherein the hypo-BioNV encapsulates and is capable of delivering one or more of perforin and granzyme to a cellular target that expresses the one or more target biomarkers.

12. The hypo-BioNV of claim 11 , wherein the hypo-BioNV a surface further comprises Fas Ligand and/or neural cell adhesion molecule (NCAM).

13. The hypo-BioNV of claim 11 , wherein the iPSC is derived from CD34+ cord blood.

14. The hypo-BioNV of claim 11 , wherein the hypo-BioNV encapsulates perforin.

15. The hypo-BioNV of claim 11 , wherein the hypo-BioNV encapsulates granzyme.

16. The hypo-BioNV of claim 11 , wherein the hypo-BioNV further encapsulates a gene editing therapeutic comprising one or more gRNA or a plasmid encoding the one or more gRNA.

17. The hypo-BioNV of claim 11 , wherein the hypo-BioNV has a size of 300 nm to 1000 nm.

18. The hypo-BioNV of claim 11 , wherein the hypo-BioNV has a size of 1000 nm to 1200 nm.

19. The hypo-BioNV of claim 11 , wherein the VERR comprises vp1, vp2, or vp3 of SVV.

20. The hypo-BioNV of claim 11 , wherein the VERR comprises HIV gp120 and gp41, or wherein the hypo-BioNV surface further comprises ApoE.

Continuity (2)
Provisional Application 62843713 · May 6, 2019
Related Publication 20220218842A1 · Jul 14, 2022
References Cited (77)
US 10675244B2 · Gho et al. · 2020 [cited by applicant]
US 20060057192A1 · Kane · 2006 [cited by applicant]
US 20080166319A1 · Schreiber et al. · 2008 [cited by applicant]
US 20160243192A1 · Seeger et al. · 2016 [cited by applicant]
US 20170080104A1 · Irvine et al. · 2017 [cited by applicant]
US 20190024065A1 · Delacote et al. · 2019 [cited by applicant]
US 20200208157A1 · Guo et al. · 2020 [cited by applicant]
US 20220040106A1 · Malcolm et al. · 2022 [cited by applicant]
US 20240307317A1 · Malcolm et al. · 2024 [cited by applicant]
EP 1447079A1 · 2004 [cited by applicant]
WO WO2015002956A1 · 2015 [cited by applicant]
WO WO2018015535A1 · 2018 [cited by applicant]
WO WO2018029656A2 · 2018 [cited by applicant]
WO WO2018175636A2 · 2018 [cited by applicant]
WO WO2018208728A1 · 2018 [cited by examiner]
WO WO2019133934A2 · 2019 [cited by applicant]
WO WO2020018620A1 · 2020 [cited by applicant]
WO WO2021003445A1 · 2021 [cited by applicant]
WO WO2021076630A1 · 2021 [cited by applicant]
WO WO2021189047A2 · 2021 [cited by applicant]
WO WO2021223659A1 · 2021 [cited by applicant]
WO WO2021231884A1 · 2021 [cited by applicant]
WO WO2022076596A1 · 2022 [cited by applicant]
WO WO2022087019A1 · 2022 [cited by applicant]
WO WO2022250880A1 · 2022 [cited by applicant]
Willms et al., Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression. Frontiers in Immunology (2018), 9:738, 1-17 (Year: 2018). [cited by examiner]
Van Dommelen et al., Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. Journal of Controlled Release (2012), 161: 635-644 (Year: 2012). [cited by examiner]
Cao et al., Seneca Valley virus attachment and uncoating mediated by its receptor anthrax toxin receptor 1. PNAS (2018), 115: 13087-13092 (Year: 2018). [cited by examiner]
Deuse et al., Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nature Biotechnology (2019), 37: 252-258 (Year: 2019). [cited by examiner]
Jalil et al., Suppressing or Enhancing Macrophage Engulfment through the Use of CD47 and Related Peptides. Bioconjugate chemistry (2022), 33: 1989-1995 (Year: 2022). [cited by examiner]
Bonilla W.V. et al. Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack. Cell Rep Med. Mar. 3, 2021;2(3):100209. [cited by applicant]
Chen Y. et al. Expression of ssDNA in mammalian cells. BioTechniques. Jan. 2003;34(1):167-71. [cited by applicant]
Chmielewski M et al. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145-54. [cited by applicant]
Curiel D. et al. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. Proc Natl Acad Sci U S A. Oct. 1, 1991;88(19):8850-4. [cited by applicant]
Davis, et al. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther. Apr. 1993;4(2):151-9. [cited by applicant]
Deuse T. et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. Mar. 2019;37(3):252-258. [cited by applicant]
Fu W. et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. Sep. 25, 2019;10(1):4355. [cited by applicant]
Gandhapudi S. et al. Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. J Immunol. Jun. 15, 2019;202(12):3524-3536. [cited by applicant]
Geller A.I. et al. An HSV-1 vector expressing tyrosine hydroxylase causes production and release of L-dopa from cultured rat striatal cells. J. Neurochem. Feb. 1995;64(2):487-96. [cited by applicant]
Geller A.I. et al., Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector. Proc Natl. Acad. Sci.: U.S.A. Aug. … [cited by applicant]
Geller A.I., et al. Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of [cited by applicant]
Goh W.J. et al. Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative. Sci Rep. Oct. 30, 2017;7(1):14322. [cited by applicant]
Goh W.J. et al. Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy. Int J Nanomedicine. Apr. 4, 2017;12:2759-2767. [cited by applicant]
Quantin, et al. Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. USA, Apr. 1, 1992;89(7):2581-4. [cited by applicant]
Singh N. et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med. May 2021;27(5):842-850. [cited by applicant]
Sonntag F. et al. AAV type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until the uncoating occurs in the nucleus. J Virol. Nov. 2006;80… [cited by applicant]
Stahnke S. et al. Intrinsic phospholipase A2 activity of AAV is involved in endosomal escape of incoming particles. Virology. Jan. 5, 2011;409(1):77-83. [cited by applicant]
Stratford-Perricadet, et al. Widespread long-term gene transfer to mouse skeletal muscles and heart. J. Clin. Invest. Aug. 1992;90(2):626-30. J Clin Invest. [cited by applicant]
Thalhauser S. et al. Presentation of HIV-1 Envelope Trimers on the Surface of Silica Nanoparticles. J Pharm Sci. Jan. 2020;109(1):911-921. [cited by applicant]
Wolfs J. et al. Biasing genome-editing events toward precise length deletions with an RNA-guided TevCas9 dual nuclease. Proc Natl Acad Sci USA. Dec. 27, 2016;113(52):14988-14993. [cited by applicant]
Wu J.Y. et al. Exosome-Mimetic Nanovesicles from Hepatocytes promote hepatocyte proliferation in vitro and liver regeneration in vivo. Sci Rep. Feb. 6, 2018;8(1):2471. [cited by applicant]
Yang H et al. PAM-Dependent Target DNA Recognition and Cleavage by C2c1 CRISPR-Cas Endonuclease. Cell. Dec. 1, 20165;167(7):1814-1828.e12. [cited by applicant]
Zadori Z et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell. Aug. 2001;1(2):291-302. [cited by applicant]
Zhang P. et al. Genetically Engineered Liposome-like Nanovesicles as Active Targeted Transport Platform. Adv Mater. Feb. 2018;30(7). [cited by applicant]
Mei Z. et al. MUC1 as a target for CART therapy in head and neck squamous cell carcinoma. Cancer Med. Jan. 2020;9(2):640-652. [cited by applicant]
Wang K. et al. GD2-specific Car T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Nat Cancer. Oct. 2020;1(10):990-997. [cited by applicant]
Bose, et al., “Bioengineered stem cell membrane functionalized nanocarriers for therapeutic targeting of severe hindlimb ischemia,” Biomaterials, vol. 185, 2018: pp. 360-370. [cited by applicant]
Chairoungdua et al., “Exosomes release of β-catenin: a novel mechanism that antagonizes Wnt signaling,” J. Cell Biol., vol. 190, No. 6, 2010: pp. 1079-1091. [cited by applicant]
Gross and Zelarayan, “The Mingle-Mangle of Wnt Signaling and Extracellular Vesicles: Functional Implications for Heart Research,” Front. Cardiovasc. Med., vol. 5, No. 10, 2018: pp. 1-8. [cited by applicant]
Urade, et al., “Endosomes differ from plasma membrane in the phospholipid molecular species composition,” Biochimica et Biophysica Acta, vol. 946, 1988: pp. 161-163. [cited by applicant]
Corbo C. et al. Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases. Nanoscale. Oct. 5, 2017;9(38):14581-14591. [cited by applicant]
Davidson et al. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat. Genet. Mar. 1993;3(3):219-23. [cited by applicant]
Felgner et al. Bethesda Res. Lab. Focus. 1989 11(2):21. [cited by applicant]
G Le Gal La Salle et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science. Feb. 12, 1993;259(5097):988-90. [cited by applicant]
Glover D. et al. Oxford Univ. Press, Oxford England. 1995. [cited by applicant]
Jang S.C. et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano. Sep. 24, 2013;7(9):7698-710. [cited by applicant]
Kaplitt M.G., et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. Oct. 1994;8(2):148-54. [cited by applicant]
Kleinstiver et al., High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets. (2016) Nature, vol. 529, No. 7587, pp. 490-495. [cited by applicant]
Lunavat T.R. et al. RNAi delivery by exosome-mimetic nanovesicles—Implications for targeting c-Myc in cancer. Biomaterials. Sep. 2016; 102:231-8. [cited by applicant]
Ma et al. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment. Theranostics, vol. 10, Issue 3, (2020) pp.… [cited by applicant]
Mannino and Gould-Fogerite. Liposome mediated gene transfer. BioTechniques. 1988;6(7):682-90. [cited by applicant]
Molinaro R. et al. Design and Development of Biomimetic Nanovesicles Using a Microfluidic Approach. Adv Mater. Apr. 2018;30(15). [cited by applicant]
Rosenfeld, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell. Jan. 10, 1992;68(1):143-55. [cited by applicant]
Sushnitha et al. Frontiers in Bioengineering and Biotechnology 8 (627): 1-17, Year: 2020. [cited by applicant]
Torres-Gomez et al. Phagocytic Integrins: Activation and Signaling (2020) Frontiers in Immunology, vol. 11, No., 738, pp. 1-10. [cited by applicant]
Yang et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. Apr. 1995;69(4):2004-15. [cited by applicant]
Yue et al. Interleukin-10 Deficiency Alters Endothelial Progenitor Cell-Derived Exosome Reparative Effect on Myocardial Repair via Integrin-Linked Kinase Enrichment. (2020) Circ Res. vol. 126, No. 3, pp. 315-329. [cited by applicant]